Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases
About This Grant
Project Summary/Abstract Obesity and metabolic disorders are leading causes of morbidity worldwide, driven in part by impaired thermogenic fat function and disrupted energy homeostasis. Beige adipocytes are inducible thermogenic fat cells within white adipose depots that play a critical role in regulating systemic metabolism by increasing energy expenditure and improving glucose and insulin homeostasis. Enhancing beige fat function represents a promising strategy for mitigating metabolic disease, yet the regulatory pathways governing beige adipogenesis, particularly in obesity, remain incompletely understood. Recent evidence from our group identifies 3- phenylpropionic acid (3-PPA), a gut microbiota-derived metabolite, as a key endogenous factor that promotes beige adipocyte formation and improves metabolic outcomes in vivo. Our preliminary data demonstrate that 3- PPA engages an immune–adipose axis involving GPR40 activation in macrophages, CXCL13 secretion, and T follicular helper (Tfh) cell recruitment. However, the broader physiological significance and therapeutic potential of this signaling axis in the context of obesity and insulin resistance remain unknown. We hypothesize that 3- PPA enhances beige adipogenesis and mitigates metabolic dysfunction through coordinated microbiota–immune–adipose interactions. To test this, we will: (1) characterize the role of GPR40-mediated signaling in macrophages during 3-PPA–induced metabolic remodeling; (2) define how CXCL13-Tfh cell interactions influence beige adipogenesis in obesity; and (3) assess the efficacy of 3-PPA-based interventions in mouse models of diet-induced obesity and metabolic disease. This research integrates metabolic physiology, immunometabolism, and microbiota-derived signaling to uncover disease-relevant mechanisms regulating thermogenic fat function. Findings may provide the foundation for novel microbiota-targeted therapies for obesity and metabolic disorders.
Grant Summary
Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis is a NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases grant providing up to $787K for university, nonprofit, healthcare org. Applications are due 2031-04-30 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $787K
2031-04-30
- 1Confirm your organization is eligible for Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis: Frequently Asked Questions
Who is eligible for the Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis?
Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis is offered by NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis provide?
Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis provides up to $787K per award from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis deadline?
Applications for Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis are due 2031-04-30 (open). Because deadlines can change, verify the date with the funder, NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis?
To apply for Gut Microbiota-Derived 3-PPA as a Metabolic Modulator of Beige Adipogenesis and Energy Homeostasis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases.